ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Health Technology

Takeda Pharmaceutical Co., Ltd.

Business Summary

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2020 JPYUSD
Revenue3,291.18B30,270.54M
Gross Profit1,789.37B16,457.72M
Operating income302,612M2,783.25M
Income before tax-60,754M-558.78M
Net income44,241M406.90M
EBITDA886,261M8,151.34M
Diluted EPS28.240.25
Dividends Per Share1801.65
Total Assets12,821.09B118,763.31M
Total liabilities8,093.60B74,972.05M
Total equity4,723.48B43,754.18M
Operating cash flow555,410M5,108.35M
Currency in JPYCurrency in USD

Historical Data

 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 1,807.37B 1,732.05B 1,770.53B 2,097.22B 3,291.18B
Gross Profit 1,161.84B 1,017.65B 1,148.86B 1,275.55B 1,789.37B
Operating income 175,770M 86,972M 195,320M 218,686M 302,612M
Income before tax 120,539M 143,346M 217,205M 127,612M -60,754M
Net income 80,166M 114,940M 186,886M 135,192M 44,241M
EBITDA 353,275M 258,398M 377,447M 466,377M 886,261M
Diluted EPS 101.71 146.25 237.55 139.82 28.24
Dividends Per Share 180 180 180 180 180
Total Assets 3,824.08B 4,346.79B 4,106.46B 13,792.77B 12,821.09B
Total liabilities 1,812.88B 2,397.82B 2,089.05B 8,606.78B 8,093.60B
Total equity 1,948.69B 1,894.26B 1,997.42B 5,181.98B 4,723.48B
Operating cash flow 26,552M 260,067M 379,600M 302,609M 555,410M
 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 15,050.91M 15,994.93M 15,974.84M 18,911.85M 30,270.54M
Gross Profit 9,675.22M 9,397.74M 10,365.80M 11,502.42M 16,457.72M
Operating income 1,463.72M 803.15M 1,762.30M 1,972.01M 2,783.25M
Income before tax 1,003.78M 1,323.75M 1,959.76M 1,150.74M -558.78M
Net income 667.58M 1,061.43M 1,686.20M 1,219.10M 406.90M
EBITDA 2,941.89M 2,386.22M 3,405.56M 4,205.58M 8,151.34M
Diluted EPS 0.84 1.35 2.14 1.26 0.25
Dividends Per Share 1.49 1.66 1.62 1.62 1.65
Total Assets 34,023.62M 39,009.18M 38,612.71M 124,612.85M 118,763.31M
Total liabilities 16,129.56M 21,518.70M 19,643.19M 77,759.25M 74,972.05M
Total equity 17,337.88M 16,999.56M 18,781.60M 46,817.41M 43,754.18M
Operating cash flow 221.11M 2,401.63M 3,424.99M 2,728.79M 5,108.35M

Valuation Measures

Mar 2020
PER116.43
ROA0.33%
ROE0.89%
Operating margin9.19%
Profit margin1.34%

Key executives

  • President, CEO & Representative Director: Christophe Weber
  • Chief Financial Officer & Director: Constantine Saroukos
  • Director, Research & Development President: Andrew S. Plump
  • Chief Ethics & Compliance Officer: Mwana Lugogo
  • Executive Officer & Global General Counsel: Yoshihiro Nakagawa

Shareholders

  • Nomura Asset Management Co., Ltd. (3.7%)
  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.3%)
  • BlackRock Fund Advisors (3.1%)
  • Nippon Life Insurance Co. (2.2%)
  • The Vanguard Group, Inc. (1.9%)
  • Nikko Asset Management Co., Ltd. (1.5%)
  • State Street Global Advisors Ltd. (1.5%)
  • Capital Research & Management Co. (World Investors) (1.5%)
  • Mondrian Investment Partners Ltd. (1.3%)
  • Wellington Management Co. LLP (1.2%)

Contact Details

Related Companies

  • Millennium Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Co. Ltd. /Europe OTC Portfolio/
  • Plasmaspendedienst GmbH
  • Gaido Health, Inc.
  • Takeda Pharmaceutical Co. Ltd. /Non Core Latin America Assets/
  • Takeda Pharmaceutical Co. Ltd. /Non Core Assets/
  • Takeda Re Insurance AG
  • Takeda Pharmaceutical Co. Ltd. /Tachosil Business/
  • Plasmapunkt Favoriten GmbH
  • Takeda Malaysia Sdn. Bhd.
  • Takeda Pharmaceutical Co. Ltd. /Latam Bus/
  • Takeda Oranienburg Real Estate GmbH & Co. KG
  • Takeda Consumer Healthcare Co., Ltd.
  • Pvp Biologics, Inc.
  • Takeda Pharmaceutical Director Incentive Plan
  • Takeda Pharmaceutical Employee Incentive Plan
  • Oy Leiras Takeda Pharmaceuticals AB
  • Takeda Architectural Design Consulting (Shanghai) Co. Ltd.
  • Takeda Pharma AB
  • Takeda Development Center Americas, Inc.
  • Takeda Ukraine LLC
  • Takeda Pharmaceuticals Taiwan Ltd.
  • Takeda SRL
  • Takeda Hellas SA
  • Takeda Christiaens SCA/CVA
  • Takeda Belgium SCA/CVA
  • Takeda Vaccines Pte Ltd.
  • Takeda Pharmaceuticals (Asia Pacific) Pte Ltd.
  • Takeda Development Center Asia Pte Ltd.
  • Takeda Pharma Sp zoo

Competitors

  • AstraZeneca PLC
  • Grifols, S.A. Class A
  • Amgen Inc.
  • Roche Holding AG
  • Amicus Therapeutics, Inc.
  • Protalix Biotherapeutics, Inc.
  • Pfizer Inc.
  • Novartis AG
  • Sanofi
  • Merck & Co., Inc.
  • AbbVie, Inc.
  • Johnson & Johnson
  • Bayer AG
  • CSL Limited
  • Bristol-Myers Squibb Company
  • Biotest AG Pref
  • UCB S.A.
  • Swedish Orphan Biovitrum AB
  • Merck KGaA
  • Novo Nordisk A/S Class B
  • ISU Abxis Co., Ltd.
  • Emmaus Life Sciences, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Hypera S.A.
  • Ipsen SA
  • Eli Lilly and Company
  • Green Cross Holdings Corporation
  • Daewoong Co., Ltd.
  • Hanmi Pharmaceutical Co., Ltd.
  • BeiGene, Ltd.
Last Updated on 8 Jul, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media